Article

Efficacy and Safety Evaluation of a Novel Botulinum Toxin Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines

Dermatologic Surgery (Impact Factor: 1.87). 11/2010; 36(s4):2111 - 2118. DOI: 10.1111/j.1524-4725.2010.01711.x
Source: PubMed

ABSTRACT BACKGROUND Botulinum toxin type A (BoNTA) is commonly injected to treat facial wrinkles. Complications include pain, erythema, bruising, and potential infection. RT001 Botulinum Toxin Type A Topical Gel (RT001) is under development for the treatment of lateral canthal lines (LCLs).OBJECTIVE To assess the efficacy and safety of RT001 for the treatment of LCLs using a randomized, double-blind, repeat-dose, placebo-controlled study design.METHODS & MATERIALS Healthy adult subjects were randomized to receive RT001 (N=19) or placebo (N=17) applied to their lateral canthal areas (LCAs). To evaluate safety of repeat exposure, treatment was administered at baseline and week 4. The primary efficacy measure was improvement in baseline LCL severity using the Investigator's Global Assessment of Lateral Canthal Line at Rest (IGA-LCL) Severity Scale.RESULTS At 8 weeks, 19 (50%) LCAs treated with RT001 showed a 2-point or greater improvement in baseline IGA-LCL severity, versus none (0%) of the placebo-treated subjects (p<.001); 36 (94.7%) LCAs treated with RT001 showed a 1-point or more improvement in baseline IGA-LCL severity, versus five (14.7%) placebo-treated LCAs (p<.001). There were no treatment-related adverse events.CONCLUSION RT001 was well tolerated and demonstrated an improvement in LCLs.This study was sponsored by Revance Therapeutics, Inc., Newark, CA.

1 Bookmark
 · 
133 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ability of cell-penetrating peptides to cross plasma membranes has been used for various applications, including the delivery of bioactive molecules to inhibit disease-producing cellular mechanisms. Selective drug delivery into target cells improves drug distribution and decreases dosing and toxicity. In this review, the authors outline the main challenges in the field, namely clarification of mechanisms of entry into cells, as well as current and future perspectives regarding cell-penetrating peptides application for human therapeutics. Here, the authors discuss some of the factors that influence efficacy of delivery and review the current status of preclinical studies and clinical trials involving the use of cell-penetrating peptide-mediated delivery of therapeutics.
    Therapeutic delivery 05/2013; 4(5):573-91.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The cosmetic use of botulinum toxin (BoNT) is the most common cosmetic procedure performed in the world today. Common adverse events seen in the aesthetic use of the BoNT include swelling, localized bruising, headaches, injection site discomfort, excessive muscle weakness, and unintended paresis of adjacent muscles. BoNT has a wide array of cosmetic uses, including treatment of glabellar lines, chemical browlift, forehead wrinkles, periorbital, and perioral lines. The future formulations and applications of BoNT type A will be plentiful, and are exciting to consider.
    Dermatologic clinics 01/2014; 32(1):23-36. · 1.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The relatively nascent field of cosmetic dermatology has seen a rapid rise in the number of products and procedures used to restore and enhance appearance. Millions of Americans undergo nonsurgical cosmetic procedures every year in the United States. The constant evolution of cosmetic dermatology introduces issues of safety and efficacy, as many of the innovative products and procedures have yet to endure the test of time. Practitioners who perform cosmetic procedures will benefit from recognizing the evidence to support the safety and efficacy of current trends in cosmetic dermatology. This article updates dermatologists on the epidemiology of cosmetic procedures in the United States, reviews recent research studying the motivations of the growing numbers of cosmetic patients, and briefly reviews the safety and efficacy of some of the most popular new nonsurgical cosmetic procedures.
    Current Dermatology Reports. 1(1).

Full-text (3 Sources)

Download
10 Downloads
Available from
Jun 2, 2014